01—Abstract
Summary
Summary of the 10-K filed March 29, 2000. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' 10-K for fiscal 1999 shows a company that returned to profitability after a difficult 1997-1998 period.
Revenue rose 11% to $356.2 milliona (from $319.9 million), gross profit grew to $174.1 million, and operating income swung to $46.8 million from an $8.1 million loss in 1998, which had included a $37.2 million in-process R&D write-off tied to the Blue Ridge Pharmaceuticals acquisition. Net income was $32.6 million, or $0.82 diluted EPS, versus a $15.2 million loss in 1998. Sales and marketing and G&A expenses were held flat-to-down, while R&D rose to $27.3 million, reflecting investment in the animal health pharmaceuticals pipeline and the VetConnect internet business.
The balance sheet remains conservative but shrank in 1999 because of capital return. The company repurchased 3.9 million shares for $64.2 millionb under a six-million-share authorization, reducing stockholders' equity to $284.3 million and cash and short-term investments to $105.4 million. Management states that current liquidity will be sufficient for the foreseeable future.
Total debt was reduced to $3.5 millionc. Investors should weigh several risks: a securities class action (Rose v.
Shaw) is being settled via a memorandum of understanding; a separate SA Scientific suit seeks $32 milliond in damages and is being contested; the company faces single-source supply dependencies (Ortho slides, Tokyo Parts analyzers, Becton hematology components); and competitive pressure is increasing in canine heartworm diagnostics. The company also disposed of its food microbiology business in late 1999 and early 2000 to sharpen its focus on veterinary markets, which generate roughly 69% of revenue.
02—Key points
Key Highlights
- Revenue grew 11% to $356.2 million in 1999, with the Companion Animal Group up 12% to $278.0 million and the Food and Environmental Division up 8% to $78.2 million.
- Operating income rebounded to $46.8 million from an $8.1 million loss in 1998, which had been depressed by a $37.2 million in-process R&D write-off from the Blue Ridge acquisition.
- Net income was $32.6 million ($0.82 diluted EPS), compared with a net loss of $15.2 million in 1998.
- Gross margin improved to 48.9% (from 49.5% in 1998 excluding... roughly stable), and sales and marketing expense fell 9% to $56.9 million, or 16% of revenue.
- The company repurchased 3.9 million shares for $64.2 million in 1999, reducing stockholders' equity to $284.3 million and cash plus short-term investments to $105.4 million.
- Total debt was cut to $3.5 million from $9.4 million, and management believes liquidity is sufficient for the foreseeable future.
- Material legal exposures include a securities class action being settled under an MOU and the SA Scientific suit seeking $8 million in actual and $24 million in punitive damages, which management is contesting.
03—Questions
Frequently Asked Questions
Why did IDEXX report a loss in 1998 but a strong profit in 1999?
The 1998 results included a $37.2 million write-off of in-process research and development from the October 1998 acquisition of Blue Ridge Pharmaceuticals, which was expensed under FASB Interpretation No. 4 because the projects had not reached technological feasibility. Excluding that charge, 1998 would have been profitable. In 1999 there was no comparable write-off, so operating income rose to $46.8 million.
How is IDEXX's business mix changing?
Veterinary diagnostic products and services made up about 69% of 1999 revenue, up from roughly 70% in 1998 in relative terms but still the core of the company. The company disposed of its food microbiology testing businesses (Acumedia, Lightning, Simplate, Bind and IDEXX Food Safety Net) in December 1999 and February 2000, a business that generated about $14 million of 1999 revenue. Management is positioning the company around veterinary diagnostics, practice information management software, veterinary pharmaceuticals and the VetConnect internet business.
What are the biggest risks to the investment case?
Key risks include heavy reliance on a few single-source suppliers (Ortho for VetTest slides, Tokyo Parts Industrial for analyzers, Becton for QBC hematology components), growing competition in canine heartworm diagnostics, dependence on new product development for analyzer growth as existing chemistry and hematology sales decline, and the outcome of pending litigation. The SA Scientific suit seeks $32 million in total damages, and the class action settlement remains subject to court approval. Quarterly results can also fluctuate because the company carries little backlog.
What is IDEXX doing with its cash and capital?
In 1999 the company bought back 3.9 million shares for $64.2 million under a board authorization of up to six million shares, and it has never paid cash dividends. It reduced debt to $3.5 million, and planned 2000 capital spending is about $22.8 million. Management says current cash, short-term investments and operating cash flow are sufficient to fund operations for the foreseeable future.
What growth bets is management making beyond core veterinary diagnostics?
The company is investing in Blue Ridge Pharmaceuticals, which has 14 products in FDA Center for Veterinary Medicine registration, including an equine protozoal myeloencephalitis treatment and a feline insulin product, and it launched the Facilitator liquid bandage in 1999. It also launched VetConnect.com, a veterinary internet portal, in January 2000. R&D spending rose to $27.3 million in 1999 partly due to these initiatives, and management acknowledges that there is no assurance these products will meet revenue or profit expectations.
04—Continue